Abstract
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal neoplasms of the gastrointestinal tract. Analysis of GIST morphology is necessary for selection of primary patients with the high risk of tumor progression for adjuvant treatment with gleevek following complete gross resection of KIT (CD 117)-positive GIST. In this study we've analyzed morphological parameters and survival of 120 GIST patients before target therapy. According to risk stratification of primary GIST by tumor location, size and mitotic index (mitoses per 50 visual fields) 44% of gastric GISTs, 87,5% of small bowel GISTs and 100% of rectum GISTs have been classified as high risk group. There was no significant difference between survival of patients with different type of GIST, Ki-67 proliferative index and presence of necrosis.
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use
-
Benzamides
-
Chemotherapy, Adjuvant
-
Diagnosis, Differential
-
Disease-Free Survival
-
Female
-
Gastrointestinal Neoplasms / enzymology
-
Gastrointestinal Neoplasms / genetics
-
Gastrointestinal Neoplasms / mortality
-
Gastrointestinal Neoplasms / pathology*
-
Gastrointestinal Stromal Tumors / enzymology
-
Gastrointestinal Stromal Tumors / genetics
-
Gastrointestinal Stromal Tumors / mortality
-
Gastrointestinal Stromal Tumors / pathology*
-
Humans
-
Imatinib Mesylate
-
Kaplan-Meier Estimate
-
Male
-
Mutation
-
Piperazines / administration & dosage
-
Piperazines / therapeutic use
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Proto-Oncogene Proteins c-kit / genetics
-
Pyrimidines / administration & dosage
-
Pyrimidines / therapeutic use
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate
-
Protein-Tyrosine Kinases
-
Proto-Oncogene Proteins c-kit